127 related articles for article (PubMed ID: 22495700)
1. HER-3 status by immunohistochemistry in HER-2-positive metastatic breast cancer patients treated with trastuzumab: correlation with clinical outcome.
Gori S; Foglietta J; Mameli MG; Stocchi L; Fenocchio D; Anastasi P; Iacono D; Del Sordo R; Basurto C; De Angelis V; Sidoni A
Tumori; 2012; 98(1):39-44. PubMed ID: 22495700
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of trastuzumab in unselected patients with HER2-positive metastatic breast cancer: a retrospective analysis.
Collovà E; Ferzi A; Scandurra G; Aurilio G; Torri V; Porcu L; Sanò MV; Taibi E; Foglietta J; Generali D; Andreis D; Dazzani MC; Bramati A; Marcon I; Atzori F; Cinieri S; Tondulli L; Grasso D; Nolè F; Petrella MC; Gori S; La Verde N
Tumori; 2014; 100(4):426-31. PubMed ID: 25296592
[TBL] [Abstract][Full Text] [Related]
3. HER3, p95HER2, and HER2 protein expression levels define multiple subtypes of HER2-positive metastatic breast cancer.
Lipton A; Goodman L; Leitzel K; Cook J; Sperinde J; Haddad M; Köstler WJ; Huang W; Weidler JM; Ali S; Newton A; Fuchs EM; Paquet A; Singer CF; Horvat R; Jin X; Banerjee J; Mukherjee A; Tan Y; Shi Y; Chenna A; Larson J; Lie Y; Sherwood T; Petropoulos CJ; Williams S; Winslow J; Parry G; Bates M
Breast Cancer Res Treat; 2013 Aug; 141(1):43-53. PubMed ID: 23959396
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of PIK3CA mutation status, PTEN and androgen receptor expression for metastasis-free survival in HER2-positive breast cancer patients treated with trastuzumab in adjuvant setting.
Adamczyk A; Niemiec J; Janecka A; Harazin-Lechowska A; Ambicka A; Grela-Wojewoda A; Domagała-Haduch M; Cedrych I; Majchrzyk K; Kruczak A; Ryś J; Jakubowicz J
Pol J Pathol; 2015 Jun; 66(2):133-41. PubMed ID: 26247526
[TBL] [Abstract][Full Text] [Related]
5. EGFR, pMAPK, pAkt and PTEN status by immunohistochemistry: correlation with clinical outcome in HER2-positive metastatic breast cancer patients treated with trastuzumab.
Gori S; Sidoni A; Colozza M; Ferri I; Mameli MG; Fenocchio D; Stocchi L; Foglietta J; Ludovini V; Minenza E; De Angelis V; Crinò L
Ann Oncol; 2009 Apr; 20(4):648-54. PubMed ID: 19188134
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of trastuzumab as a single agent in heavily pretreated patients with HER-2/neu-overexpressing metastatic breast cancer.
Sawaki M; Ito Y; Tada K; Mizunuma N; Takahashi S; Horikoshi N; Kasumi F; Akiyama F; Sakamoto G; Imai T; Nakao A; Hatake K
Tumori; 2004; 90(1):40-3. PubMed ID: 15143970
[TBL] [Abstract][Full Text] [Related]
7. HER2/HER3 heterodimers and p21 expression are capable of predicting adjuvant trastuzumab response in HER2+ breast cancer.
Green AR; Barros FF; Abdel-Fatah TM; Moseley P; Nolan CC; Durham AC; Rakha EA; Chan S; Ellis IO
Breast Cancer Res Treat; 2014 May; 145(1):33-44. PubMed ID: 24706169
[TBL] [Abstract][Full Text] [Related]
8. The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine.
Ross JS; Slodkowska EA; Symmans WF; Pusztai L; Ravdin PM; Hortobagyi GN
Oncologist; 2009 Apr; 14(4):320-68. PubMed ID: 19346299
[TBL] [Abstract][Full Text] [Related]
9. HER-2/neu status of primary breast cancer and corresponding metastatic sites in patients with advanced breast cancer treated with trastuzumab-based therapy.
Pectasides D; Gaglia A; Arapantoni-Dadioti P; Bobota A; Valavanis C; Kostopoulou V; Mylonakis N; Karabelis A; Pectasides M; Economopoulos T
Anticancer Res; 2006; 26(1B):647-53. PubMed ID: 16739334
[TBL] [Abstract][Full Text] [Related]
10. Impact of HER-2-targeted therapy on overall survival in patients with HER-2 positive metastatic breast cancer.
Berghoff AS; Bago-Horvath Z; Dubsky P; Rudas M; Pluschnig U; Wiltschke C; Gnant M; Steger GG; Zielinski CC; Bartsch R
Breast J; 2013; 19(2):149-55. PubMed ID: 23350584
[TBL] [Abstract][Full Text] [Related]
11. Lapatinib or Trastuzumab Plus Taxane Therapy for Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: Final Results of NCIC CTG MA.31.
Gelmon KA; Boyle FM; Kaufman B; Huntsman DG; Manikhas A; Di Leo A; Martin M; Schwartzberg LS; Lemieux J; Aparicio S; Shepherd LE; Dent S; Ellard SL; Tonkin K; Pritchard KI; Whelan TJ; Nomikos D; Nusch A; Coleman RE; Mukai H; Tjulandin S; Khasanov R; Rizel S; Connor AP; Santillana SL; Chapman JA; Parulekar WR
J Clin Oncol; 2015 May; 33(14):1574-83. PubMed ID: 25779558
[TBL] [Abstract][Full Text] [Related]
12. Long-term tumor remission under trastuzumab treatment for HER2 positive metastatic breast cancer - results from the HER-OS patient registry.
Witzel I; Müller V; Abenhardt W; Kaufmann M; Schoenegg W; Schneeweis A; Jänicke F
BMC Cancer; 2014 Nov; 14():806. PubMed ID: 25371387
[TBL] [Abstract][Full Text] [Related]
13. Brain metastases from breast cancer: prognostic significance of HER-2 overexpression, effect of trastuzumab and cause of death.
Le Scodan R; Jouanneau L; Massard C; Gutierrez M; Kirova Y; Cherel P; Gachet J; Labib A; Mouret-Fourme E
BMC Cancer; 2011 Sep; 11():395. PubMed ID: 21929800
[TBL] [Abstract][Full Text] [Related]
14. Loss of human epidermal growth factor receptor 2 (HER2) expression in metastatic sites of HER2-overexpressing primary breast tumors.
Niikura N; Liu J; Hayashi N; Mittendorf EA; Gong Y; Palla SL; Tokuda Y; Gonzalez-Angulo AM; Hortobagyi GN; Ueno NT
J Clin Oncol; 2012 Feb; 30(6):593-9. PubMed ID: 22124109
[TBL] [Abstract][Full Text] [Related]
15. Time to first tumor progression as outcome predictor of a second trasuzumab-based therapy beyond progression in HER-2 positive metastatic breast cancer.
Metro G; Giannarelli D; Gemma D; Lanzetta G; Ciccarese M; Papaldo P; Gamucci T; Lorusso V; Mottolese M; Magnolfi E; Cognetti F; Fabi A
Breast J; 2010; 16(1):66-72. PubMed ID: 19889170
[TBL] [Abstract][Full Text] [Related]
16. PTEN, Akt, MAPK, p53 and p95 expression to predict trastuzumab resistance in HER2 positive breast cancer.
Duman BB; Sahin B; Acikalin A; Ergin M; Zorludemir S
J BUON; 2013; 18(1):44-50. PubMed ID: 23613387
[TBL] [Abstract][Full Text] [Related]
17. Insulin-like growth factor-1 receptor (IGF-1R) expression does not predict for resistance to trastuzumab-based treatment in patients with Her-2/neu overexpressing metastatic breast cancer.
Köstler WJ; Hudelist G; Rabitsch W; Czerwenka K; Müller R; Singer CF; Zielinski CC
J Cancer Res Clin Oncol; 2006 Jan; 132(1):9-18. PubMed ID: 16184380
[TBL] [Abstract][Full Text] [Related]
18. Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer (EORTC 75111-10114): an open-label, randomised, phase 2 trial from the Elderly Task Force/Breast Cancer Group.
Wildiers H; Tryfonidis K; Dal Lago L; Vuylsteke P; Curigliano G; Waters S; Brouwers B; Altintas S; Touati N; Cardoso F; Brain E
Lancet Oncol; 2018 Mar; 19(3):323-336. PubMed ID: 29433963
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of paclitaxel given once per week along with trastuzumab and pertuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer.
Dang C; Iyengar N; Datko F; D'Andrea G; Theodoulou M; Dickler M; Goldfarb S; Lake D; Fasano J; Fornier M; Gilewski T; Modi S; Gajria D; Moynahan ME; Hamilton N; Patil S; Jochelson M; Norton L; Baselga J; Hudis C
J Clin Oncol; 2015 Feb; 33(5):442-7. PubMed ID: 25547504
[TBL] [Abstract][Full Text] [Related]
20. Brain metastases in patients who receive trastuzumab-containing chemotherapy for HER2-overexpressing metastatic breast cancer.
Ono M; Ando M; Yunokawa M; Nakano E; Yonemori K; Matsumoto K; Kouno T; Shimizu C; Tamura K; Katsumata N; Fujiwara Y
Int J Clin Oncol; 2009 Feb; 14(1):48-52. PubMed ID: 19225924
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
